CN109568336B - Composition of platinum compound and chondroitin sulfate and application thereof - Google Patents

Composition of platinum compound and chondroitin sulfate and application thereof Download PDF

Info

Publication number
CN109568336B
CN109568336B CN201811637539.2A CN201811637539A CN109568336B CN 109568336 B CN109568336 B CN 109568336B CN 201811637539 A CN201811637539 A CN 201811637539A CN 109568336 B CN109568336 B CN 109568336B
Authority
CN
China
Prior art keywords
composition
chondroitin sulfate
molar ratio
cells
lobaplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811637539.2A
Other languages
Chinese (zh)
Other versions
CN109568336A (en
Inventor
华子春
穆飞飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou High-Tech Research Institute Of Nanjing University
Targetpharma Laboratories Jiangsu Co ltd
Original Assignee
Changzhou High-Tech Research Institute Of Nanjing University
Targetpharma Laboratories Jiangsu Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou High-Tech Research Institute Of Nanjing University, Targetpharma Laboratories Jiangsu Co ltd filed Critical Changzhou High-Tech Research Institute Of Nanjing University
Priority to CN201811637539.2A priority Critical patent/CN109568336B/en
Publication of CN109568336A publication Critical patent/CN109568336A/en
Application granted granted Critical
Publication of CN109568336B publication Critical patent/CN109568336B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the field of organic synthesis and pharmaceutical chemistry, in particular to a composition of a platinum compound and chondroitin sulfate and application thereof. The platinum compound and the chondroitin sulfate disclosed by the invention are combined and used for administration, can be applied to preparation of antitumor drugs, and pharmacological experiments show that the platinum compound and the chondroitin sulfate have obvious antitumor effects on different cancer cells, and specifically comprise the following components: the composition combining the platinum compound and the chondroitin sulfate has an obvious anti-tumor effect, and the toxic and side effects caused by single administration of the platinum compound and the chondroitin sulfate can be effectively relieved by combining the composition; the combined composition has potential development value for novel high-efficiency, low-toxic-side-effect and drug-resistance anti-tumor drugs.

Description

Composition of platinum compound and chondroitin sulfate and application thereof
Technical Field
The invention relates to the field of organic synthesis and pharmaceutical chemistry, in particular to a composition, a preparation method and application thereof.
Background
Cancer is a common frequently-occurring disease seriously harming human health, and overcoming the problem that cancer cells are always hot in domestic and foreign research. Chemotherapy is a major anti-malignant method for systemic therapy, but it also damages other cells while fighting tumor cells. Therefore, the search for a low-toxicity and highly effective antitumor drug is urgent for antitumor treatment.
Platinum anti-tumor compounds have become indispensable and the most widely applied drugs in cancer chemotherapy. Since 1978, cisplatin was first approved as a first-generation antitumor Drug by Food and Drug Administration (FDA), platinum antitumor drugs began to enter the visual field of people and were rapidly applied to clinical treatment of various malignant tumors, and platinum antitumor compounds such as carboplatin, nedaplatin, oxaliplatin, leplatin, heptaplatin, lobaplatin, and miboplatin were listed in various countries. Domestic and foreign researches show that after the platinum compounds enter cells of a human body, most of the conjugates generated by combining the platinum compounds with substances in the cells can have cytotoxicity, so that the platinum compounds have the effect of resisting tumors. The mechanism of action of platinum antineoplastic compounds with cancer cells can be summarized by the following steps: after being injected into cells, the platinum anti-tumor compound is hydrolyzed in cytoplasm and reacts with water to form a positively charged hydrate, and the positively charged hydrate enters cell nucleus under the action of electrostatic attraction to form a complex with DNA, so that the replication and transcription of the DNA are hindered, and the apoptosis of the cells is caused.
The composition of the invention combines a platinum compound and a polysaccharide compound, namely chondroitin sulfate, and measures the anti-tumor effect of the composition on different cancer cells. The composition can reduce the dosage of platinum drugs, and has better anti-tumor effect after combination.
Disclosure of Invention
In order to solve the problem of large toxic and side effects of the existing platinum compound medicines used as the antitumor medicines, the invention aims to provide a composition of a platinum compound and chondroitin sulfate, and the composition is applied to the preparation of the antitumor medicines. Wherein, the platinum compounds are divided into three types of cisplatin, lobaplatin and oxaliplatin.
The invention is realized by the following technical method:
cell proliferation assay (MTT method):
(1) preparing 2 × 10 cancer cells in logarithmic growth phase4Each cell/mL suspension was added at 100. mu.L per well in a 96-well plate.
(2) Reagent control group, tumor cell control group and experiment groups with various compositions with different concentrations are set. Before the experiment, the single medicines of cisplatin, lobaplatin and oxaliplatin are respectively added into the tumor cells (the invention also tries to select three platinum compounds with the best effect for subsequent research except the three platinum compounds, such as carboplatin, nedaplatin, miboplatin, leplatin, heptaplatin and the like), so as to obtain the final concentrations of the cisplatin, lobaplatin and oxaliplatin, and further obtain the IC50 concentrations of the three medicines. Chondroitin sulfate with different concentrations is added for combined administration. The following combination experiment was then started. Experimental component single drug groups and combined drug groups.
(3) The reagent control group was supplemented with an equal amount of medium, and the tumor cell control group was supplemented with an equal amount of the same medium without drug, 3 parallel wells per dose. Firstly, CO is first introduced2Culturing in an incubator, adding 10 mu L of 0.5 percent MTT into each well, continuing culturing, finally adding 100 mu L of triple dissolving solution, decoloring overnight until the MTT is completely dissolved, and measuring the absorbance (A) of each well at 570nm and 630nm of an automatic enzyme-labeled reading instrument to calculate the inhibition rate and IC 50.
Preferably, the final concentrations of cisplatin, lobaplatin and oxaliplatin in step (1) are 5, 50, 500, 5000 and 50000 ng/mL.
Preferably, step (2) is carried out in CO2The culture time in the incubator is 12-36 h, and the time for continuing the culture after adding MTT is 2-6 h.
Preferably, the composition of the platinum compound and the chondroitin sulfate has a molar ratio of the chondroitin sulfate to the lobaplatin of 0.02-3.2; the molar ratio of the chondroitin sulfate to the cisplatin composition is 0.005-4.8; the molar ratio of the chondroitin sulfate to the oxaliplatin composition is 0.017-12.8.
The invention has the beneficial effects that:
the evaluation of the Q value of the inhibition effect of the combination of the platinum compound and the chondroitin sulfate on cancer cell lines shows that the composition has good tumor inhibition effect on the cancer cell lines, and the inhibition effect on the cancer cell lines is different due to different types of the two medicines in the composition. The inhibitory effect of the composition on cancer cell lines is related to the dosage range of the combination of platinum and polysaccharide. The dosage of the combination administration of the composition is obviously lower than the clinical dosage, and the safety is good. The invention can be used for preparing medicaments for treating tumors, can provide a new application of the composition in medicine, and particularly relates to an application of the composition in preparing novel medicaments for resisting tumors.
The present invention will be described in further detail with reference to the following examples, but the scope of the present invention is not limited to the specific examples, but is defined by the claims.
Detailed Description
In the patent, the cisplatin, lobaplatin and oxaliplatin compounds are combined with polysaccharide polymers except chondroitin sulfate, and the composition also has good anti-tumor effect, but chondroitin sulfate with relatively good effect is selected for research.
Example 1
Cell lines and culture: hepatoma cell 2 strain (BEL-7402, Hep-G2), pancreatic cancer cell 5 strain (BxPC-3, Capan-1, Colo357, Miapaca-2, Panc-1), lung cancer cell 6 strain (A427, A549, NCI-H1299, NCI-H2170, NCI-H358, NCI-H460), colorectal cancer cell 3 strain (Colo205, Lovo, RKO), breast cancer cell 6 strain (HCC-1806, MCF-7, MDA-MB-231, MDA-MB-361, MDA-436, TD-47), cervical cancer cell 1 strain (Hela), which were offered by Nanjing university, DMEM/RPMI 1640/McCoy' 5a medium containing 10% fetal bovine serum, at 37 ℃ in 5% CO2Culturing in an incubator, changing the culture solution once in 2-3 days, and taking the cells in the logarithmic growth phase for experiment.
Cell proliferation assay (MTT method): preparing 2 × 10 cancer cells in logarithmic growth phase4Each cell/mL suspension was added at 100. mu.L per well in a 96-well plate. A reagent control group, a tumor cell control group and experimental groups of various medicines with different concentrations are arranged. Before the experiment, single medicines of cisplatin, lobaplatin and oxaliplatin are respectively added into tumor cells, so that the final concentrations of the cisplatin, lobaplatin and oxaliplatin are 5, 50, 500, 5000 and 50000ng/mL, the IC50 concentrations of the three medicines are obtained, and chondroitin sulfate with different concentrations is added for combined administration. The following combination experiment was then started. Experimental component single drug groups and combined drug groups. The reagent control group was supplemented with an equal amount of medium, and the tumor cell control group was supplemented with an equal amount of the same medium without drug, 3 parallel wells per dose. In CO2After 24h of culture in an incubator, 10 mu L of 0.5 percent MTT is added into each well for further culture for 4h, 100 mu L of triple dissolving solution is added, the mixture is decolorized overnight until the MTT is completely dissolved, and the absorbance (A) of each well is measured at 570nm and 630nm of an automatic enzyme-labeled reading instrument, and the inhibition rate and IC50 are measured.
And (4) analyzing results:
(1) combined administration of lobaplatin and chondroitin sulfate
Lobaplatin was administered in combination with chondroitin sulfate, and the results are shown in Table 1. According to analysis, for the liver cancer cell HepG2, when the molar ratio of the chondroitin sulfate to the lobaplatin in the composition is 0.64, the inhibition rate of the chondroitin sulfate to the tumor is increased by 147 percent; for pancreatic cancer cells Colo357, when the molar ratio of chondroitin sulfate to lobaplatin in the composition is 0.64, the inhibition rate of the composition on tumors is increased by 129%; for pancreatic cancer cells Panc-1, when the molar ratio of chondroitin sulfate to lobaplatin in the composition is 0.04-0.64, the inhibition rate of the chondroitin sulfate to tumors is increased by 152% -205%; for pancreatic cancer cells, Capan-2, when the molar ratio of chondroitin sulfate to lobaplatin in the composition is 0.64, the inhibition rate of the chondroitin sulfate to lobaplatin on tumors is increased by 148%; for the lung cancer cell A427, when the molar ratio of the chondroitin sulfate to the lobaplatin in the composition is 0.02-0.64, the inhibition rate of the chondroitin sulfate to the tumor is increased by 141% -157%; for the lung cancer cell NCI-H2170, when the molar ratio of the chondroitin sulfate to the lobaplatin in the composition is 0.64, the inhibition rate of the chondroitin sulfate to the lobaplatin is increased by 156 percent; for lung cancer cells NCI-H358, when the molar ratio of chondroitin sulfate to lobaplatin in the composition is 0.64, the inhibition rate of the chondroitin sulfate to lobaplatin on tumors is increased by 142 percent; for colon cancer cell A549, when the molar ratio of the chondroitin sulfate to the lobaplatin in the composition is 3.2, the inhibition rate of the composition on tumors is increased by 122%; for the colon cancer cells RKO, when the molar ratio of the chondroitin sulfate to the lobaplatin in the composition is 1.6, the inhibition rate of the composition on tumors is increased by 134 percent; for breast cancer cells HCC1806, when the molar ratio of chondroitin sulfate to lobaplatin in the composition is 0.64, the inhibition rate of the composition on tumors is increased by 129%; for breast cancer cells TD-47, when the molar ratio of chondroitin sulfate to lobaplatin in the composition is 0.64, the inhibition rate of the composition on tumors is increased by 142%; for the breast cancer cells MM436, when the molar ratio of the chondroitin sulfate to the lobaplatin in the composition is 2.1, the inhibition rate of the chondroitin sulfate to the lobaplatin on tumors is increased by 144%.
TABLE 1
Figure BDA0001930381930000061
Figure BDA0001930381930000071
Figure BDA0001930381930000081
(2) Combined administration of cisplatin and chondroitin sulfate
Cisplatin was co-administered with chondroitin sulfate and the results are shown in table 2. According to analysis, for the liver cancer cell HepG2, when the molar ratio of the chondroitin sulfate to the cisplatin in the composition is 1.2, the inhibition rate of the chondroitin sulfate to the cisplatin on tumors is increased by 117%; for the lung cancer cell A427, when the molar ratio of the chondroitin sulfate to the cisplatin in the composition is 2.4, the inhibition rate of the chondroitin sulfate to the cisplatin on tumors is increased by 136 percent; for colon cancer cell A549, when the molar ratio of the chondroitin sulfate to the cisplatin in the composition is 4.8, the inhibition rate of the composition on tumors is increased by 164 percent; for colon cancer cells Color205, when the molar ratio of chondroitin sulfate to cisplatin in the composition is 0.02, the inhibition rate of the composition on tumors is increased by 119%; for colon cancer cells HF29, when the molar ratio of chondroitin sulfate to cisplatin in the composition is 0.01-0.48, the inhibition rate of the composition on tumors is increased by 136% -167%; for breast cancer cells MM231, when the molar ratio of chondroitin sulfate to cisplatin in the composition is 4.8, the inhibition rate of the composition on tumors is increased by 148%; for a cervical cancer cell Hela, when the molar ratio of the chondroitin sulfate to the cisplatin in the composition is 0.6-2.4, the inhibition rate of the chondroitin sulfate to the tumor is increased by 115% -119%, and when the molar ratio of the chondroitin sulfate to the cisplatin in the composition is 0.075-0.15, the inhibition rate of the chondroitin sulfate to the cisplatin in the composition is increased by 119% -122%. Chondroitin sulfate showed no cytotoxic effect on almost all tumor cells within the determined concentration range.
TABLE 2
Figure BDA0001930381930000091
Figure BDA0001930381930000101
Figure BDA0001930381930000111
(3) Combined administration of oxaliplatin and chondroitin sulfate
Oxaliplatin was administered in combination with chondroitin sulfate, and the results are shown in table 3. According to analysis, for pancreatic cancer cells, the Capan-2 has 269% increase in the inhibition rate of the tumor when the molar ratio of chondroitin sulfate to oxaliplatin in the composition is 12.8; for the lung cancer cell A427, when the molar ratio of the chondroitin sulfate to the oxaliplatin in the composition is 12.8, the inhibition rate of the composition on tumors is increased by 127 percent; for colon cancer cells A549, when the molar ratio of the chondroitin sulfate to the oxaliplatin in the composition is 4.27, the inhibition rate of the composition on tumors is increased by 139%; for breast cancer cells TD-47, when the molar ratio of chondroitin sulfate to oxaliplatin in the composition is 12.8, the inhibition rate of the composition on tumors is increased by 165 percent. Chondroitin sulfate showed no cytotoxic effect on almost all tumor cells within the determined concentration range.
TABLE 3
Figure BDA0001930381930000121
Figure BDA0001930381930000131
Figure BDA0001930381930000141
Figure BDA0001930381930000151
In addition to the study on the inhibition rate of the combination of the platinum compound and the chondroitin sulfate, the patent also studies the inhibition rate of the single administration of the platinum compound on the tumor and the inhibition rate of the single administration of the chondroitin sulfate on the tumor. Since the inhibition rate is significantly less than that of the combination when administered alone, the inhibition rate of the individual administration is not overly described in the methods of the invention.
(4) Inhibition rate of platinum compound alone:
TABLE 4
Figure BDA0001930381930000152
Figure BDA0001930381930000161
Figure BDA0001930381930000171
(5) Inhibitory rate of chondroitin sulfate administered alone:
TABLE 5
Figure BDA0001930381930000181
The invention combines the platinum compound and the chondroitin sulfate and applies the platinum compound and the chondroitin sulfate to the preparation of the antitumor drugs. The two medicines are combined for use, so that the dosage of the platinum medicine can be reduced, and the combined anti-tumor effect is better; the combination of the two can improve the sensitivity of tumor cells to platinum drugs; the platinum compounds have different types, and the anti-tumor effect of the composition is different; the combination of the platinum compound and the chondroitin sulfate has a certain dosage relation.
The invention also tries that the types and specific varieties of other cell strains except liver cancer cell strains, pancreatic cancer cell strains, lung cancer cell strains, colorectal cancer cell strains, breast cancer cell strains and cervical cancer cell strains mentioned in the specification generate certain tumor inhibition effect; the invention also tries the combination of platinum compounds except lobaplatin, cisplatin and oxaliplatin with chondroitin sulfate to generate certain effect of enhancing and inhibiting tumor; the invention also tries to combine the polysaccharide compound except the chondroitin sulfate with different platinum compounds for administration, which can enhance the anti-tumor effect; the invention also tries to combine the composition of the platinum compound and the chondroitin sulfate with the conventional anti-tumor compound, so as to further improve the anti-tumor effect. The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are only exemplary embodiments of the present invention, and are not intended to limit the present invention, and any modifications, equivalents, improvements and the like made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (1)

1. The application of a composition of a platinum compound and chondroitin sulfate in preparing a synergistic anti-tumor cell medicament is characterized in that the composition consists of the platinum compound and the chondroitin sulfate; wherein the platinum compound is one of cispofoil, lobaplatin and oxaliplatin respectively; for the tumor cells which are liver cancer HepG2 cells, the molar ratio range of the composition of the chondroitin sulfate and the lobaplatin is 0.16-0.64 and 0.02; for the tumor cells which are pancreatic cancer Colo357 cells, the molar ratio of the composition of the chondroitin sulfate and the lobaplatin is 0.32-0.64; for the pancreatic cancer Panc-1 cells serving as the tumor cells, the molar ratio of the composition of the chondroitin sulfate and the lobaplatin is 0.04-0.64; for the tumor cells which are pancreatic cancer Capan-2 cells, the molar ratio of the composition of the chondroitin sulfate and the lobaplatin is 0.07-1.1; for the tumor cells are lung cancer A427 cells, the molar ratio of the composition of the chondroitin sulfate and the lobaplatin is 0.02-0.64; for the tumor cells are lung cancer NCI-H2170 cells, the molar ratio of the composition of the chondroitin sulfate and the lobaplatin is 0.32-0.64; for the tumor cells are lung cancer NCI-H358 cells, the molar ratio of the composition of the chondroitin sulfate and the lobaplatin is 0.04-0.64; for the tumor cell is lung cancer A549 cell, the molar ratio of the composition of chondroitin sulfate and lobaplatin is 3.2; for the tumor cell being colorectal cancer RKO cell, the molar ratio range of the composition of chondroitin sulfate and lobaplatin is 0.4-3.2; for the tumor cells are breast cancer HCC1806 cells, the molar ratio of the composition of the chondroitin sulfate and the lobaplatin is in the range of 0.04 and 0.16-0.64; for the tumor cells which are breast cancer TD-47 cells, the molar ratio of the composition of the chondroitin sulfate and the lobaplatin is 0.16-0.64; for the tumor cells, breast cancer MM436 cells, the molar ratio of the composition of chondroitin sulfate and lobaplatin is 2.1; for the tumor cell which is a colorectal cancer Colo205 cell, the molar ratio of the composition of the chondroitin sulfate and the cisplatin is 0.01-0.02; for the tumor cell which is a cervical cancer Hela cell, the molar ratio of the chondroitin sulfate to the cisplatin composition is 0.075-0.15 and 0.6-2.4; for said tumor cell to be a colorectal cancer RKO cell, the molar ratio of the composition of chondroitin sulfate to cisplatin is 0.2; for the tumor cell which is colorectal cancer HT-29, the molar ratio of the composition of the chondroitin sulfate and the cisplatin is 0.02-0.48; for the tumor cells which are liver cancer Bel7402 cells, the molar ratio range of the composition of chondroitin sulfate and oxaliplatin is 0.4 and 3.2-6.4; for the tumor cells which are pancreatic cancer BxPC-3 cells, the molar ratio of the composition of the chondroitin sulfate and the oxaliplatin is 0.4-0.8; for the tumor cells to be lung cancer A427 or NCI-H460 cells, the molar ratio of the composition of chondroitin sulfate and oxaliplatin is 12.8; for the tumor cell is a lung cancer H358 cell, the molar ratio of the composition of chondroitin sulfate and oxaliplatin is 6.4; for the tumor cells are lung cancer A549 cells, the molar ratio of the composition of the chondroitin sulfate and the oxaliplatin is 0.267-4.27 and 0.067; for the tumor cell being colorectal cancer Lovo cell, the molar ratio of the composition of chondroitin sulfate and oxaliplatin is 0.8-1.6; and for the tumor cells which are colorectal cancer Colo205 cells, the molar ratio of the composition of the chondroitin sulfate and the oxaliplatin is 0.033-4.27.
CN201811637539.2A 2018-12-29 2018-12-29 Composition of platinum compound and chondroitin sulfate and application thereof Active CN109568336B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811637539.2A CN109568336B (en) 2018-12-29 2018-12-29 Composition of platinum compound and chondroitin sulfate and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811637539.2A CN109568336B (en) 2018-12-29 2018-12-29 Composition of platinum compound and chondroitin sulfate and application thereof

Publications (2)

Publication Number Publication Date
CN109568336A CN109568336A (en) 2019-04-05
CN109568336B true CN109568336B (en) 2021-10-08

Family

ID=65932621

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811637539.2A Active CN109568336B (en) 2018-12-29 2018-12-29 Composition of platinum compound and chondroitin sulfate and application thereof

Country Status (1)

Country Link
CN (1) CN109568336B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1762330A (en) * 2005-10-13 2006-04-26 上海交通大学 Medicine-loading sustained-releasing nanosphere alimentary tract stent
CN1824319A (en) * 2005-12-20 2006-08-30 济南康泉医药科技有限公司 Hormone kind anticancer medicine slow release agent
WO2011012312A1 (en) * 2009-07-31 2011-02-03 Fresenius Kabi Deutschland Gmbh Bladder instillation compositions for treating bladder cancer
CN105025904A (en) * 2012-09-04 2015-11-04 埃莱森制药有限责任公司 Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3905293A (en) * 1992-04-17 1993-11-18 Seikagaku Corporation Platinum complex and antineoplastic agent
US20060199204A1 (en) * 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20070248541A1 (en) * 2003-12-01 2007-10-25 Mitsubishi Pharma Corporation Liposome
US20080300389A1 (en) * 2007-06-04 2008-12-04 Yang David J Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1762330A (en) * 2005-10-13 2006-04-26 上海交通大学 Medicine-loading sustained-releasing nanosphere alimentary tract stent
CN1824319A (en) * 2005-12-20 2006-08-30 济南康泉医药科技有限公司 Hormone kind anticancer medicine slow release agent
WO2011012312A1 (en) * 2009-07-31 2011-02-03 Fresenius Kabi Deutschland Gmbh Bladder instillation compositions for treating bladder cancer
CN105025904A (en) * 2012-09-04 2015-11-04 埃莱森制药有限责任公司 Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin;Jing-Shi Zhang et al.;《Inorganic Compounds》;20000711;第74卷;第200页摘要部分；第301页Materials and methods部分 *
Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C;Jing-Shi Zhang et al;《International Journal of Pharmaceutics》;20021231;第240卷;第23页摘要部分 *
Stability of a Cisplatin–Chondroitin Sulfate A Complex in Plasma and Kidney in Terms of Protein Binding;Jing-Shi ZHANG et al;《Biol. Pharm. Bull》;20011231;第24卷(第8期);第970页摘要部分 *
硫酸软骨素在医学上的应用概况;曹岳华等;《中南药学》;20100331;第8卷(第3期);第222第223页 5.抗肿瘤部分 *
铂类药物的毒性作用与预防措施;王林 等;《医药导报》;20050331;第24卷(第3期);第255页7.3部分 *
铂类金属抗肿瘤药物的应用与研究进展;翁琳等;《中国药学杂志》;20050831;第40卷(第16期);第1205-1208页 *

Also Published As

Publication number Publication date
CN109568336A (en) 2019-04-05

Similar Documents

Publication Publication Date Title
TW201615197A (en) The new cancer therapy indication of the PROCHLORPERAZINE MALEATE
RU2011142806A (en) PENTAMIDINE COMBINATIONS FOR CANCER TREATMENT
CN112274525B (en) Chemotherapy pharmaceutical composition and application thereof
US10675259B2 (en) Drug combination with antitumor effects
CN104434939B (en) Antitumor medicament composition of panax notoginseng saponins R7 and oridonin with capabilities of reducing toxicity and enhancing efficacy and application of antitumor medicament composition
CN109568336B (en) Composition of platinum compound and chondroitin sulfate and application thereof
AU2016204180B2 (en) Mogrosides and the salts thereof, the preparing method and the use of the same and pharmaceutical compositions comprising the mogrosides and the salts thereof
CN109602760B (en) Composition of platinum compound and heparin compound and application thereof
CN106913571A (en) A kind of medicine and its application for treating tumour
CN104523674B (en) A kind of composition for injection using oxaliplatin as main ingredient composition
CN109512825A (en) A kind of composition and its application of platinum-like compounds and Sodium Hyaluronate
CN102688228B (en) Pharmaceutical composition containing apigenin, apigenin derivative, rubescensin and rubescensin derivative, and application thereof
EP4122480A1 (en) Use of astragalus medicinal composition for preparing drug for enhancing cancer therapy
CN104146999B (en) Rubescensine A and Docetaxel attenuation synergistic antineoplastic pharmaceutical compositions and application thereof
CN107286123A (en) A kind of preparation method of dibenzofuran class compound and application
CN114642665A (en) Pharmaceutical composition containing palbociclib and 10-hydroxycamptothecin and application
CN104055786B (en) The application in preparation preventing and treating tumour medicine of medicagenic acid-3-O-β-D-pyranglucoside, medicagenic acid and salt thereof
CN103520222A (en) Cordyceps militaris extractive and application thereof in preparation of medicines for treating tumors
WO2009096245A9 (en) Pharmaceutical composition and combined agent
CN109528763A (en) The composition of cis-platinum and Sodium Hyaluronate
US20220168319A1 (en) COMBINED USE OF A-NOR-5alpha ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG
CN111544580B (en) Anti-cancer pharmaceutical composition
CN107519494B (en) Medicinal composition containing liriope muscari baily saponins C
CN114617894B (en) Pharmaceutical composition and application thereof in preparation of medicine for treating colon cancer
CN106310264B (en) Composition comprising dithiole and 2-pyrrolidinone derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant